ASCEND-2 and ASCEND-3 trials: Ceritinib in ALK-rearranged NSCLC with brain metastases - European Medical Journal

ASCEND-2 and ASCEND-3 trials: Ceritinib in ALK-rearranged NSCLC with brain metastases

Oncology

At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD, from Lausanne University Hospital, Lausanne, Switzerland, discusses results from ASCEND-2 and ASCEND-3, both of which are single-arm, open-label, multicentre phase 2 clinical trials evaluating the efficacy and safety of ceritinib, a tyrosine kinase inhibitor, in patients with ALK-rearranged non-small cell lung cancer (NSCLC) and baseline brain metastases.

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>